Sign in

Philip Bejon

@philipbejon.bsky.social
177 followers 170 following 184 posts

Director @modmedmicro.bsky.social; Previous Director @kemri_wellcome; Researcher on vaccines, malaria, viruses; Clinical Microbiologist, Infectious Disease, General Medicine

PostsRepliesMedia
Reposted by Philip Bejon
Sam Lipworth @samlipworth.bsky.social · 05/10/2026
We're offering a great DPhil opportunity to look at comparing E. coli strain dynamics in gut in health and disease with ultimate aim of developing novel therapeutics. Opportunity to learn wet and dry lab skills including long-read metagenomics, biostastical + ex-vivo modelling. Happy to chat pls RT!
ndm.ox.ac.uk
022
Philip Bejon @philipbejon.bsky.social · 01/10/2026
I often see instructions to cut word count in the same email with reviewers comments on additional paragraphs for the intro, methodology clarifications, additional papers to cite, limitations to acknowledge, "could the authors also comment on...."
100
Philip Bejon @philipbejon.bsky.social · 01/10/2026
I think positivity is with a denominator of all patients getting cultured, so implies that less is less - i.e. cultures no better targeted on real bacteraemia, so assuming patient mix did not change, implies that culture shortage led to less detection in absolute terms?
000
Reposted by Philip Bejon
Bash the bug @bashthebug.net · 29/09/2026
Infusoria BioArt exhibition exploring microbiology opens at the John Radcliffe Hospital! 📅 26 September – 6 November 2026 📍 Artlink Corridor Gallery, John Radcliffe Hospital, Oxford #ArtAndScience #Microbiology #AntimicrobialResistance #InfectionPrevention #PublicEngagement
bashthebug.net
Infusoria BioArt exhibition exploring microbiology opens at the John Radcliffe Hospital
BioArt exhibition exploring microbiology opens at the John Radcliffe Hospital A new display of work by artist Anna Dumitriu is now on show at the John Radcliffe Hospital, bringing together art, microbiology and research into healthcare-associated infections. The exhibition draws on research from Modernising Medical Microbiology into hospital environments, bacteria and antimicrobial resistance. Through BioArt, Anna’s work explores the microbial world that usually remains unseen and encourages people to think differently about the relationship between microorganisms, healthcare and our surroundings.
045
Reposted by Philip Bejon
Sam Lipworth @samlipworth.bsky.social · 30/09/2026
Great new work from @dotnagy.bsky.social who has developed EpiSENTRY which performs sample size calculations for public health WGS surviellance studies. She applies to data from the NEKSUS study to estimate how much sequencing is enough for GNBSI surviellance in England. @modmedmicro.bsky.social
medrxiv.org
How much is enough? Optimising sampling frames for genomic surveillance of Escherichia coli and Klebsiella spp. bloodstream infections - a retrospective study
Background: Optimising sampling frames for genomic surveillance of E. coli and Klebsiella may support interventions to mitigate bloodstream infections (BSIs), but approaches to estimating sample size ...
0109
Philip Bejon @philipbejon.bsky.social · 21/09/2026
And we see such complex algorithms in our minds for responding to CRP levels, all of them unevidenced and often leading to more antibiotics.
020
Reposted by Philip Bejon
NEJM.org @nejm.org · 16/09/2026
In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months. Full SOLARIO trial results: nej.md/4dgrqwY
This image shows a forest plot showing the robustness of the primary analysis results. Subgroups include definite treatment failure, definite or probable treatment failure, and definite, probable, or possible treatment failure. Hazard ratios with 95% confidence intervals are displayed, indicating whether a short duration is better than a long duration. A red line indicates the noninferiority margin.
074
Reposted by Philip Bejon
Ilan Schwartz @germhuntermd.bsky.social · 17/09/2026
Less is more, ortho-ID edition Another game changer in ortho ID from the group that brought you OVIVA Pts with ortho infections who underwent curative surgery (no DAIR) with local implantation of abx were randomized to <=7d vs >=4w ABx No Dif in 12 mo relapse www.nejm.org/doi/full/10.... #IDSky
Forest plot with primary analysis results which shows no difference in definite treatment failure, definite/probable treatment failure, or definite/probable/possible treatment failure according to treatment durationForest plot showing subgroup analysis which shows no difference between shorter and longer duration antibiotics in any of the subgroups including prosthetic infection, Staph aureus mono infection, and whether local gentamicin was used in mono therapy or combination therapy
23217
Philip Bejon @philipbejon.bsky.social · 18/09/2026
Agree, although I think even with OVIVA and bone infection practice generally there is a high degree of pre-op planning - e.g. implications of retention of metalwork vs removal for treatment plan, adequacy of debridement possible or not possible and so on.
130
Reposted by Philip Bejon
Michael Marks @drmichaelmarks.bsky.social · 14/09/2026
Cutaneous leishmaniasis is a major problem in Ethiopia & often requires admission for systemic therapy. Liquid nitrogen cryotherapy is an option but also has significant logistic barriers. We evaluated leveraging CO2 cryotherapy deployed for cervical cancer to decenteralise treatment for CL.
journals.plos.org
Diagnosis of localized cutaneous leishmaniasis and treatment outcomes following carbon dioxide cryotherapy performed by health centre staff: A pilot implementation study in Ethiopia
Author summary Cutaneous leishmaniasis (CL) is a neglected tropical disease (NTD) of the skin caused by species of the genus Leishmania. It is endemic in Ethiopia’s highland regions. Affected individu...
121
Philip Bejon @philipbejon.bsky.social · 14/09/2026
Vapes can bring their own problems, but hard to deny the importance of quitting tobacco, the difficulty of quitting, and that they seem to help.
000
Philip Bejon @philipbejon.bsky.social · 11/09/2026
The bioinformatic criteria that support clinical metagenomics as important as the wet lab workflow, and needs principled approach with derivation and validation to avoid overfitting.
000
Philip Bejon @philipbejon.bsky.social · 11/09/2026
If we say "any read counts" then lots of false +ve. If "only lots of reads" then lots of false -ve. Best compromise is ≥2 reads as threshold. But including number of reads in other samples in the same flowcell as an additional criteria helps exclude barcode crossover.
100
Philip Bejon @philipbejon.bsky.social · 11/09/2026
Detailed reflections: Serious technical limits applying metagenomics at scale. Lots of host DNA, and at scale need multiple samples per flow cell. So often trying to detect a few reads. And combining samples means crossover between samples, giving false positives. Bioinformatics is key.
110
Philip Bejon @philipbejon.bsky.social · 11/09/2026
Motivation was that using targeted PCR is limiting, want untargeted approach without relying on many primers. So metagenomics. We used workflow with ONT, 51% sensitive all viruses and 99.8% specific. Can improve sens to 70% by bioinformatics (more below) and to 83% excluding low level viruses.
100
Philip Bejon @philipbejon.bsky.social · 11/09/2026
New publication from @modmedmicro.bsky.social on metagnomic RNA virus detection from upper respiratory samples - www.sciencedirect.com/science/arti... @nickdsandy.bsky.social @treestreet.bsky.social @dotnagy.bsky.social @samlipworth.bsky.social @oxfordbrc.bsky.social
sciencedirect.com
Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens
Clinical metagenomics (CMg) offers high-throughput respiratory pathogen detection with a wider range than targeted, probe-dependent diagnostics. Seque…
126
Reposted by Philip Bejon
Bash the bug @bashthebug.net · 03/09/2026
Microbiology is coming out of the lab! Infusoria, a new exhibition by MMM Artist-in-Residence Anna Dumitriu, runs in the JR Hospital from 26 Sept–6 Nov 2026. New works inspired by Oxford research explore hospital sinks, wastewater, water microbiomes and antimicrobial resistance.
bashthebug.net
When microbiology becomes art: Infusoria
Infusoria 26 September – 6 November 2026Artlink Corridor Gallery, John Radcliffe Hospital, Oxford From hospital sinks to BioArt: our microbiology research inspires new exhibition Infusoria What does the microbial world of a hospital sink look like when viewed not only through the lens of microbiology, but through art? Research from Modernising Medical Microbiology (MMM) at the University of Oxford&hellip;
045
Philip Bejon @philipbejon.bsky.social · 03/09/2026
That will be interesting. When does it report? I know this provokes polarizing reactions, but there are also trials of CBT type interventions, some positive (pubmed.ncbi.nlm.nih.gov/37155736/) and some negative (pubmed.ncbi.nlm.nih.gov/41212544/).
100
Philip Bejon @philipbejon.bsky.social · 03/09/2026
I guess worth noting that in both studies many individuals improve over time whichever group they were in, which seems hopeful against the "none of the drugs work" point.
120
Reposted by Philip Bejon
KEMRI-Wellcome @kemriwellcome.bsky.social · 02/09/2026
Congratulations to our Executive Director, Prof. Edwine Barasa, on his appointment to the renewed @who.int Science Council, joining 20 leading scientists globally. The Council will advise on emerging technologies,breakthroughs & high-priority health issues shaping global health. 🔗: shorturl.at/hQybK
044
Reposted by Philip Bejon
edwinebarasa.bsky.social @edwinebarasa.bsky.social · 01/09/2026
Honoured to be appointed to the WHO Science Council, joining 20 leading scientists from around the world to help shape the future of science, research and innovation for global health. Excited about the work ahead. @kemriwellcome.bsky.social www.who.int/news/item/27...
who.int
WHO appoints 21 leading scientists to Science Council to help shape future health breakthroughs
The WHO Science Council is an advisory body established by the WHO Director-General to provide independent advice on high-priority scientific issues, emerging technologies, and advances in science and...
024
Reposted by Philip Bejon
BK. Titanji @boghuma.bsky.social · 27/08/2026
An outbreak of Mpox is unfolding in Guinea Bissau. Madagascar is also experiencing its first ever outbreak. I would argue that Mpox never left. We have not made the necessary investments in global surveillance and targeted immunization. www.theguardian.com/global-devel...
theguardian.com
Mpox is back – and in new countries. How can this outbreak be contained?
The public health emergencies in 2022 and 2024 saw the virus reported in 145 countries, but in the new cases children appear particularly affected
38853
Reposted by Philip Bejon
BK. Titanji @boghuma.bsky.social · 21/08/2026
Our new review is out! We examine the JAK/STAT pathway as a therapeutic target in chronic viral infections, including HIV, hepatitis viruses, SARS-CoV-2 & herpesviruses and the balance between reducing harmful inflammation while preserving antiviral immunity. www.frontiersin.org/journals/imm...
frontiersin.org
Frontiers | Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation
The discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway as a key regulator of immune function and inflammation ...
14412
Reposted by Philip Bejon
Oxford Medical Sciences Division @medsci.ox.ac.uk · 19/08/2026
NEWS: 100th patient enrolled in PARTNERS trial to identify the first effective treatments for Bundibugyo ebolavirus disease @psioxford.bsky.social 
medsci.ox.ac.uk
100th patient enrolled in PARTNERS trial to identify the first effective treatments for Bundibugyo ebolavirus disease
This milestone, reached just 12 weeks after the announcement of the outbreak, makes PARTNERS the fastest-ever randomised controlled trial of treatments for Ebola.
042
Reposted by Philip Bejon
RTarlinton.bsky.social @rtarlinton.bsky.social · 18/08/2026
This sort of work is what public health should be , patient, collaborative, consistent , over a long enough period of time to really see what’s happening ( and a fantastic drop in childhood deaths to boot)
023
Reposted by Philip Bejon
Katja @jaggakatja.bsky.social · 18/08/2026
Great news!! This drop in hospitalisations and deaths in children due to malaria really need to be more widely appreciated!
021
Reposted by Philip Bejon
BK. Titanji @boghuma.bsky.social · 18/08/2026
This is truly great work. Thanks for sharing and congratulations to the team.
042
Reposted by Philip Bejon
Hannah Slater @hannahslater.bsky.social · 18/08/2026
Great article and an important message - there's a lot of emphasis on the next hot new malaria intervention, but always important to remember that the fundamentals done really well can have a huge and sustained impact.
041
Philip Bejon @philipbejon.bsky.social · 18/08/2026
Hats off to @alice-kamau.bsky.social for leading analysis. Funded @wellcometrust.bsky.social support @kemriwellcome.bsky.social @ox.ac.uk @clairelisekessler.bsky.social @melissa-a-penny.bsky.social @melissakapulu.bsky.social @tropicalmedicine.ox.ac.uk @ndm.ox.ac.uk @boghuma.bsky.social
140
Philip Bejon @philipbejon.bsky.social · 18/08/2026
So without much fanfare, a quiet corner of surveillance data shows that simple interventions have massively changed mortality. Probably represents a lot of Africa but we don't have complete data. Full paper here: link.springer.com/content/pdf/...
link.springer.com
131
Philip Bejon @philipbejon.bsky.social · 18/08/2026
So why? Final snip shows, despite climate change, not to do with overall rainfall (panel A), but masses of bednets distributed since 2008 (panel B), more and more use to date, and also drug treatment has improved (panel C).
130
Philip Bejon @philipbejon.bsky.social · 18/08/2026
Second snip shows mortality due to malaria. Similar pattern, goes from 0.5 per 1000 children dying per year (massive mortality from one single pathogen) down to no deaths 2021-24. From a major killer to nothing.
130
Philip Bejon @philipbejon.bsky.social · 18/08/2026
First snip shows background malaria prevalence in community (panel A) and admissions per 1000 children (panel B). Huge drop from peaks in 1990/1999, to lows in 2008, slight rise to 2014 (we worried about resurgence due to less immunity) but then, unexpectedly falls to nothing in 2021-24.
130
Philip Bejon @philipbejon.bsky.social · 18/08/2026
Kilifi is a coastal County in Kenya, where @kemriwellcome.bsky.social has undertaken 35 years sentinel surveillance of malaria. Dramatic changes that I think aren't widely appreciated. Work led by @alice-kamau.bsky.social Highlights and link to paper:
2146
Philip Bejon @philipbejon.bsky.social · 18/08/2026
Oh, yes that is different, and I assumed not allowed. Dusty rejection response deserved. Nevertheless, desk decisions include some random noise, so even though "not on" I guess the tactic works with journals with randomly allocated editors, or if individual memory is less reliable.
000
Philip Bejon @philipbejon.bsky.social · 18/08/2026
Because we are incentivized to get things into high impact journals, and more tickets to the lottery sometimes works. Not defending it, but survival instincts are often more powerful than dignity.
110
Reposted by Philip Bejon
Global Health EDCTP3 @globalhealthedctp3.bsky.social · 30/06/2026
Investing in people, creating lasting impact #EDCTP-supported researcher Prof. Abdoulaye Djimdé has been featured in Nature for his contribution to advancing the fight against malaria and strengthening African-led research capacity. 🔗 Read the article: www.nature.com/articles/d44...
062
Reposted by Philip Bejon
KEMRI-Wellcome @kemriwellcome.bsky.social · 29/06/2026
🎓Fully funded PhD opportunity! 🔬Ready to make an impact in child health research? Apply for the PhD studentship under the RECOVER study and help improve care for children with severe acute malnutrition. 🔗Apply here👉: shorturl.at/RqNiS 🗓️Deadline : July 3, 2026
013
Philip Bejon @philipbejon.bsky.social · 20/06/2026
Except here, superiority is defined as OR<1.0 - i.e. any little difference - the same as the pitfall of the frequentist presentation. (This is geeky detail by the way, it is a fabulous trial and a practice-changing result).
110
Philip Bejon @philipbejon.bsky.social · 20/06/2026
I think SCOUT says single dose fosfo was less good, there was no single dose nitrofurantion or pivmecillinam arm. Can assume they wouldn't have done gone well either. Two dose fosfo was similar in cure rates to nitro/piv, despite those being 5 and 3 day courses.
110
Reposted by Philip Bejon
Michael Marks @drmichaelmarks.bsky.social · 17/06/2026
Come work @lshtm.bsky.social modelling STIs in UK & evaluation of new interventions. 3yr research fellow modelling post - feel free to get in touch to discuss. Current closing date 30th June @rozeggo.bsky.social @adamjkucharski.bsky.social @grahammedley.bsky.social @drlouisedyson.bsky.social
jobs.lshtm.ac.uk
Job Opportunity at LSHTM: Research Fellow
The London School of Hygiene & Tropical Medicine (LSHTM) is one of the world’s leading public health universities. Our mission is to improve health and health equity in the UK and worldwide; working i...
0814
Philip Bejon @philipbejon.bsky.social · 10/06/2026
That was the sentence that leapt out for me as well.
020
Reposted by Philip Bejon
Ursula Hofer @hoferu.bsky.social · 10/06/2026
"[...] as of May 27, 2026, approximately 280–2520 cases of Bundibugyo virus disease might have occurred in [DRC] (estimate range 306–2521 with the back-calculation model and 282–1345 with the geographical spread model); however, there is considerable uncertainty around these estimates."
121
Reposted by Philip Bejon
Ursula Hofer @hoferu.bsky.social · 10/06/2026
Updated modelling of the current size of the Ebola outbreak by Imperial and collaborators. Ruth McCabe and co-authors did an incredible job at integrating continuously changing case data 👇
thelancet.com
Estimation of the Ebola outbreak size in the Democratic Republic of the Congo
The ongoing outbreak of Bundibugyo virus disease, a form of Ebola virus disease caused by the Bundibugyo virus, in the Democratic Republic of the Congo is evolving rapidly. As of May 27, 2026, 1031 su...
233
Reposted by Philip Bejon
KEMRI-Wellcome @kemriwellcome.bsky.social · 09/06/2026
🚨Vaccinology webinar alert!🚨 🧪Curious about how vaccines are developed and standardized? Join our next webinar session with Dr. Selorm Avumegah, @cepi.net, and learn how standards ensure the quality, safety, and effectiveness of vaccines. 🗓️June 24th, 2026 🕑2:00 PM – 3:30 PM EAT 🔗: shorturl.at/4zUWK
013
Reposted by Philip Bejon
KEMRI-Wellcome @kemriwellcome.bsky.social · 09/06/2026
🫀How can Africa tackle the growing burden of hypertension? 📚Our latest research highlights why combining proven interventions with locally generated evidence is key to developing solutions that work for African populations. 🔗Read more here 👉: shorturl.at/7FAf4
013
Philip Bejon @philipbejon.bsky.social · 08/06/2026
But those with delay were less immunosuppressed, less confused, less febrile - as might be expected - so arguably outcomes would have been worse in the early treatment group without the early acyclovir.
010
Reposted by Philip Bejon
Bash the bug @bashthebug.net · 01/06/2026
NIHR webinar on BashTheBug on YouTube BashTheBug was originally a large international citizen science project that invited anyone to help us classify how well different samples of M. tuberculosis grew in the presence of a range of antibiotics. It ran from 2017 to 2021 and in that time 46,427…
bashthebug.net
NIHR webinar on BashTheBug on YouTube
BashTheBug was originally a large international citizen science project that invited anyone to help us classify how well different samples of M. tuberculosis grew in the presence of a range of antibiotics. It ran from 2017 to 2021 and in that time 46,427 people took part and collectively they classified 4,746,420 images of M. tuberculosis growing on different concentrations of one of 13 antibiotics. 
022
Reposted by Philip Bejon
University of Oxford @ox.ac.uk · 01/06/2026
NEW: An Oxford-developed vaccine candidate targeting the Bundibugyo strain of Ebola has received backing from CEPI, accelerating efforts to respond to the epidemic in the Democratic Republic of the Congo and Uganda. More info ➡️ bit.ly/4uif4KI
Illustration of an Ebola virus particle with a headline about CEPI backing for an Oxford Bundibugyo ebolavirus vaccine candidate.
0149
Reposted by Philip Bejon
Bash the bug @bashthebug.net · 28/05/2026
Thanks to the team for all their hardwork preparing and delivering the activities, especially in this heatwave! 🌞🌞🌞
033